Mologic Ltd, a developer of powerful, personalised diagnostics to improve the lives of patients, today announced that it has signed agreements with medical technology companies, Medisur and Peripal AG to distribute PERiPLEX®, a rapid point-of-care (POC) test for the detection of infection in patients on peritoneal dialysis (PD). Both companies are specialists in the development and distribution of products which enable patient self-management and will supply PERiPLEX as part of a highly complementary product portfolio in key European markets including France, Germany, Italy, The Netherlands, Austria and Switzerland.
PERiPLEX detects two critical biomarkers of infection in PD waste fluid using a lateral flow immunoassay system and provides a visual result within 10 minutes. “Establishing a global distribution network is integral to Mologic’s product commercialisation strategy. With the appointment of distributors across Europe we will ensure PERiPLEX is available to more patients, giving them greater choice and the confidence to monitor their dialysis at home. Medisur and Peripal share our mission to improve the lives of patients by bringing diagnostics and treatment closer to home, and with highly complementary product portfolios, we look forward to working together.” said Mark Davis, co-founder and CEO at Mologic.
The PERiPLEX technology was developed following a collaborative project with Cardiff University Medical School, funded by the National Institute of Health Research (NIHR).
To find out more about PERiPLEX visit: https://mologic.co.uk/periplex/